Related Experiment Video
Updated: Jul 2, 2025
Pancreatic Tissue Dissection to Isolate Viable Single Cells
Published on: May 26, 2023
Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review
Francis P Robertson1, Andrew Cameron2, Harry V M Spiers3
1Department of HPB Surgery, Glenfield Hospital, Leicester, UK; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Background:
Pancreatic Ductal Adenocarcinoma (PDAC) patients exhibit varied responses to multimodal therapy. RNA gene sequencing has unravelled distinct tumour biology subtypes, forming the focus of this review exploring its impact on survival outcomes.
Methods:
A systematic search across PubMed, Medline, Embase, and CINAHL databases targeted studies assessing long-term overall and disease-free survival in PDAC patients with molecular subtyping.
Results:
Fifteen studies including 2731 patients were identified. Molecular subtyping was performed by RNA sequencing and Immunohistochemistry in 14 studies and by Mass Spectrometry in 1 study. Two main tumour subtypes were identified (classical and basal-like or squamous) with basal like associated with poorer outcomes. Further subtypes were identified in individual studies. Superior survival was seen with classical subtype in all other analyses that compared the classical and basal subtypes. High risk stromal subtypes were identified on further analysis of the stroma and were associated with a worse survival independent of the tumour subtype.
Conclusion:
Molecular subtyping of PDAC specimens can identify patients with high-risk tumour biology and poor survival outcomes. Routine subtyping is limited by the cost of RNA sequencing and the volume of raw data generated which has made its translation into routine clinical practice difficult.
